Management and Treatment of Myopericarditis
Treat myopericarditis with NSAIDs (aspirin 750-1000 mg every 8 hours or ibuprofen 600 mg every 8 hours) plus colchicine (0.5 mg twice daily if ≥70 kg, 0.5 mg once daily if <70 kg) for 3 months, with mandatory exercise restriction until symptoms resolve and CRP, ECG, and echocardiogram normalize. 1
First-Line Pharmacologic Therapy
The cornerstone of treatment combines two medications that work synergistically:
NSAIDs (Class I recommendation):
- Aspirin: 750-1000 mg every 8 hours for 1-2 weeks 1
- Ibuprofen: 600 mg every 8 hours for 1-2 weeks 1
- Always provide gastroprotection 1
- Taper gradually: decrease aspirin by 250-500 mg every 1-2 weeks, ibuprofen by 200-400 mg every 1-2 weeks 1
- Duration is guided by symptoms and CRP normalization 1
Colchicine (Class I recommendation as adjunct therapy):
- Weight-based dosing: 0.5 mg twice daily if ≥70 kg; 0.5 mg once daily if <70 kg 1
- Duration: 3 months minimum 1
- No loading dose required 1
- Tapering not mandatory, but can use 0.5 mg every other day in final weeks for patients <70 kg 1
- Critical benefit: Colchicine halves the recurrence rate from 15-30% to approximately 7-15% 1
Recent evidence specifically supports colchicine in myopericarditis: a 2024 study demonstrated that colchicine reduced recurrences from 43.8% to 19.2% (p=0.001) in patients with first-attack pericarditis with myocardial involvement, with only mild side effects in 1.7% of patients 2.
Exercise Restriction (Critical for Myopericarditis)
Non-athletes: Restrict physical activity beyond ordinary sedentary life until complete resolution of symptoms AND normalization of CRP, ECG, and echocardiogram 1
Athletes: Minimum 3-month restriction from competitive sports after symptom onset, even after normalization of all parameters 1
This restriction is more stringent than simple pericarditis because myocardial involvement carries theoretical risks during the inflammatory phase 3, 4.
Monitoring Treatment Response
Use CRP as the primary biomarker to guide treatment duration and assess response 1. Continue therapy until:
- Symptoms completely resolve
- CRP normalizes
- ECG normalizes
- Echocardiogram normalizes
When First-Line Therapy Fails
Corticosteroids should NOT be first-line (Class III recommendation) 1 because they:
- Increase recurrence rates (up to 50% after first recurrence) 1
- Promote chronicity and drug dependence 1
- Favor more recurrences and side effects 1
Consider low-dose corticosteroids ONLY if:
- True contraindication to NSAIDs (allergy, recent GI bleeding, high bleeding risk on anticoagulation) 1
- Failure of adequate doses of NSAIDs plus colchicine 1
- Specific indications (autoimmune disease, post-pericardiotomy syndrome, pregnancy) 1
- Infectious causes (especially bacterial, TB) have been excluded 1
If corticosteroids are necessary:
- Use low to moderate doses: prednisone 0.2-0.5 mg/kg/day 1
- Add as triple therapy with NSAIDs and colchicine—do not replace them 1
- Taper extremely slowly, especially below 15 mg/day prednisone 1
- Below 15 mg/day: decrease by only 1.25-2.5 mg every 2-6 weeks 1
Common Pitfalls to Avoid
Using corticosteroids first-line: This is the most common error and dramatically increases recurrence risk 1
Inadequate treatment duration: Stopping NSAIDs or colchicine too early is a common cause of recurrence 1
Allowing premature return to exercise: Particularly dangerous in myopericarditis given myocardial involvement 3, 4
Rapid corticosteroid tapering: If steroids are used, tapering too quickly (especially below 15 mg/day) triggers recurrences 1
Not monitoring CRP: This objective marker should guide all treatment decisions 1
Prognosis
Most patients with viral or idiopathic myopericarditis have excellent long-term prognosis with preserved left ventricular function 1. Troponin elevation does not confer worse prognosis when LV function is preserved 3. Complete remission typically occurs within 3-6 months 3. The risk of constrictive pericarditis is <1% for idiopathic/viral cases 1.